Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
New research suggests that artificial intelligence (AI) may have a significant impact in reducing prostate biopsies for PI-RADS 3 lesions on magnetic resonance imaging (MRI).
For the retrospective study, recently presented at the Radiological Society of North America (RSNA) conference, researchers evaluated an AI model for 302 PI-RADS lesions in a total of 248 patients. All patients in the cohort had MRI/ultrasound-guided fusion biopsy preceded by multiparametric MRI, according to the study. The study authors noted that 44 of the 302 biopsies were positive for clinically significant prostate cancer (csPCa).1
The researchers noted a prostate-specific antigen density (PSAD) > .15 ng/mL2 was associated with a greater than sixfold likelihood of csPCa in PI-RAD 3 index lesions but only a 61 percent sensitivity. However, when the AL model was combined with the PSAD threshold, the study authors noted a 17 percent increase in sensitivity (78 percent) and a 93 percent negative predictive value (NPV).1
New research presented at the recent RSNA conference showed the combination of AI model and a prostate-specific antigen density (PSAD) > .15 ng/mL2 had a 78 percent sensitivity and a 93 percent negative predictive value (NPV) for clinically significant prostate cancer (csPCa) in PI-RADS 3 lesions. (Image courtesy of Adobe Stock.)
“Combining a bpMRI-based AI model with PSAD can notably enhance the diagnostic process for patients with PI-RADS 3 lesions,” wrote lead study author Omer Esengur, M.D., a postdoctoral researcher associated with the Molecular Imaging Branch of the National Institutes of Health (NIH).
(Editor’s note: For additional coverage of RSNA, click here.)
While the AI model itself had an overall sensitivity of 57 percent and specificity of 62 percent for diagnosing csPCa, the researchers noted it still offered promise in ruling out csPCa with an 89 percent NPV.1
“The AI model alone demonstrated a high NPV, particularly in detecting csPCa, which is crucial for minimizing unnecessary biopsies,” added Esengur and colleagues.
Reference
1. Esengur OT, Yilmaz EC, Ozyoruk KB, et al. Multimodal approach to optimize biopsy-decision-making for PI-RADS 3 lesions at multiparametric MRI. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
Recent Videos
Related Content
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025Article
In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Podcast
Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Article
Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Article
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
